What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor design-Reference-Cited by-同舟云学术

What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor design

Published:2021-01-18 Issue:4 Volume:41 Page:1965-1998
ISSN:0198-6325
Container-title:Medicinal Research Reviews
language:en
Short-container-title:Med Res Rev

Author:

Xiong Muya¹²^ORCID,Su Haixia¹²,Zhao Wenfeng¹,Xie Hang¹,Shao Qiang¹²^ORCID,Xu Yechun¹²³^ORCID

Affiliation:

1. CAS Key Laboratory of Receptor Research|Drug Discovery and Design Center, Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai China

2. University of Chinese Academy of Sciences Beijing China

3. School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study University of Chinese Academy of Sciences Hangzhou China

Funder

Science and Technology Commission of Shanghai Municipality

National Natural Science Foundation of China

Publisher

Wiley

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/med.21783

Reference117 articles.

1. A MURINE VIRUS (JHM) CAUSING DISSEMINATED ENCEPHALOMYELITIS WITH EXTENSIVE DESTRUCTION OF MYELIN

2. A New Virus Isolated from the Human Respiratory Tract.

3. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease.

4. Effects of a "new" human respiratory virus in volunteers.

5. Coronavirus antibody titres in sera of healthy adults and experimentally infected volunteers

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor;Current Medicinal Chemistry;2024-11

2. Discovery of the potent covalent inhibitor with an acrylate warhead for SARS-CoV-2 3CL protease;Bioorganic & Medicinal Chemistry Letters;2024-11

3. Are protein–ligand docking programs good enough to predict experimental poses of noncovalent ligands bound to the SARS-CoV-2 main protease?;Drug Discovery Today;2024-10

4. Crystal structures of coronaviral main proteases in complex with the non-covalent inhibitor X77;International Journal of Biological Macromolecules;2024-09

5. Development of novel antivrial agents that induce the degradation of the main protease of human-infecting coronaviruses;European Journal of Medicinal Chemistry;2024-09